SEC Form 4 · accession 0001209191-15-052410

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Interim CFO

Period of report

Jun 10, 2015

Accepted (ET)

Jun 11, 2015 · 6:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 10, 2015	M	1,500	$11.91	A	4,486	D
Common Stock	Jun 10, 2015	M	875	$21.92	A	5,361	D
Common Stock	Jun 10, 2015	M	1,750	$68.48	A	7,111	D
Common Stock^F1	Jun 10, 2015	S	4,125	$93.50	D	2,986	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F2	$11.91	Jun 10, 2015	M	1,500	D	—	Jan 3, 2022	Common Stock	1,500	875	D
Employee Stock Option (right to buy)^F3	$21.92	Jun 10, 2015	M	875	D	—	Feb 15, 2023	Common Stock	875	1,312	D
Employee Stock Option (right to buy)^F4	$68.48	Jun 10, 2015	M	1,750	D	—	Apr 1, 2024	Common Stock	1,750	4,250	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.50 to $93.515, inclusive. The reporting person undertakes to provide, upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 01/03/2012.
F3Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 02/15/2013.
F4Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 04/01/2014.